Any feedback?
Literature summary for 3.4.21.43 extracted from
- Synergy between two active sites of human complement receptor type 1 (CD35) in complement regulation: implications for the structure of the classical pathway C3 convertase and generation of more potent inhibitors (2005), J. Immunol., 175, 4528-4535.
Inhibitors
| Inhibitors | Comment | Organism | Structure |
|---|---|---|---|
| N-terminal long homologous repeat A of complement receptor type 1 | responsible for dissociation of enzyme. Highest decay accelerating activity for mutant dimeric construct N-terminal long homologous repeat A (D109N/E116K)/N-terminal long homologous repeat A (D109N) | Homo sapiens |
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Homo sapiens | - |
- |
- |
Subunits
| Subunits | Comment | Organism |
|---|---|---|
| dimer | dimeric structure of enzyme on cell surfaces, binding studies | Homo sapiens |
| More | enzyme subunit C3b binds to site 2 of complement receptor type 1 | Homo sapiens |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
